ProfileGDS5678 / 1443413_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 3% 2% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 11.918722
GSM967853U87-EV human glioblastoma xenograft - Control 21.880922
GSM967854U87-EV human glioblastoma xenograft - Control 31.892462
GSM967855U87-EV human glioblastoma xenograft - Control 41.831742
GSM967856U87-EV human glioblastoma xenograft - Control 51.845852
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 11.947492
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 21.88722
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.868142
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.863972
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 11.880572
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.873552
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.862052
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 41.918893
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 51.876092